CLDF Title
Home | Contact Us | Bookmark
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Committee Members Conference Highlights

Live CME Meetings

Beginning Date

July 2020

Ending Date

December 2020



Target Audience

This educational program is targeted at healthcare providers who treat NASH.


This initiative will provide education on emerging advances in research and expert recommendations in the management of veteran patients with NASH.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the pathogenesis and natural history of NAFLD/NASH and the impact on fibrosis outcomes
  • Describe current recommendations or guidelines related to screening and diagnosis of NASH
  • Effectively incorporate the current standard of care/guidelines for diagnosis and management of NAFLD/NASH into clinical practice
  • Discuss the benefits and limitations of current diagnostic modalities and treatment options for NAFLD/NASH
  • Describe recent evidence regarding new and emerging noninvasive diagnostic modalities for NASH
  • Describe the mechanisms of action of novel agents for the treatment of NASH
  • Discuss recent evidence regarding the safety and efficacy of emerging agents for the treatment of NASH
  • Accreditation Statement

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and The Chronic Liver Disease Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation:

    Purdue University College of Pharmacy designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Disclosure Statement:

    All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

    All additional planning committee members, staff and reviewers of The Chronic Liver Disease Foundation and Purdue University College of Pharmacy have no relationships to disclose.

    Americans with Disabilities Act:

    The event staff will be glad to assist you with any special needs (i.e., physical, dietary). Please contact us prior to the event at 1-888-565-5321.

    This program is supported by an educational grant from Intercept Pharmaceuticals.

    Accredited by:

    Provided by:

    • Speaker
    • Date
    • Time
    • Venue/Location Information
    • Stephen Harrison, MD
    • Wednesday 07/15/2020
    • 6:00 PM
    • Teleweb-CDT
      Central Daylight Time, CO
    • Register
    Slide Library
    Abstract Library
    Slide Library
    Abstract Library
    Slide Library
    Abstract Library
    Slide Library
    Abstract Library
    Slide Library
    Abstract Library
    Slide Library
    About CLDF
    Mission Statement
    Board of Trustees
    Board of Advisors/Faculty
    2019 GI Fellow Board of Advisors
    Other Resources
    Liver News Library
    Journal Abstracts
    Hep C Link to Care
    Centers of
    Educational Expertise
    Substance Use Disorder
    CLDF Follow Us
      The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
    © Copyright 2012-2020 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
    Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.